慢加急性乙型肝炎肝衰竭患者肝组织IFN-r酌、TNF-α和IL-10的表达*

doi:10.3969/j.issn.1672-5069.2011.02.012

Abstract

Abstract: Objectives This study attempted to determine intrahepatic expressions of proinflammatory and anti-inflammatory cytokines in patients with acute-on-chronic liver failure（ACLF）arosing from HBV infection. Methods In situ expressions of interferon（IFN-γ），tumor necrosis factor（TNF-α）and interleukin 10 （IL-10）were analyzed in the livers of patients with ACLF，chronic hepatitis B（CHB），and normal controls（NC）by using immunohistochemistry. Results Intrahepatic IFN-γ and TNF-α expressions were markedly up-regulated in patients with ACLF as compared to CHB and NC（both P<0.001）；However，similar IL-10 expressions were observed in ACLF and CHB；IFN-γ over-expression was actively correlated with expression of TNF-α（r=0.886，P<0.001）. Conclusions The imbalanced expression of proinflammatory and anti-inflammatory cytokines may contribute to immuno-pathogenesis in HBV-infected ACLF.

Key words: Acute-on-chronic liver failure, Interferon, Tumor necrosis factor, Interleukin-10, Immunohistochemistry

TIAN Hui，SUN Ying，TENG Guangju，et al.. Imbalanced intrahepatic expression of interferon gamma，tumor necrosis factor alpha，and interleukin-10 in hepatitis B virus infection patients with acute-on-chronic liver failure[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2011, 14(2): 116-118.

References

[1] SEN S，WILLIAMS R，JALAN R. The pathophysiological basis of acute-on-chronic liver failure[J]. Liver，2002，22（suppl 2）:5-13.
[2] JALAN R，WILLIAMS R. Acute-on-chronic liver failure: pathophysiological basis of therapeutic options[J]. Blood Purif， 2002，20:252-261.
[3] WASMUTH HE，KUNZ D，YAGMUT E，et al. Patients with acute on chronic liver failure display‘sepsis-like’immune paralysis[J]. Hepatology，2005，42:195-201.
[4] 邹正升，陈菊梅，辛绍杰，等. 慢性重型病毒性肝炎发病特点的探讨[J]. 中华实验和临床病毒学杂志，2002，16（4）：322-325.
[5] 王宇明，陈耀凯，顾长海，等. 重型肝炎命名和诊断分型的再认识—附477例临床分析[J]. 中华肝脏病杂志，2000，8（5）：261-263.
[6] ANDO K，MORIYAMA T，GUIDOTTI LG，et al. Mechanisms of class I restricted immunopathology:A trangenic mouse model of fulminant hepatitis[J]. Exp Med，1993，178:1541-1554.
[7] OHTA A，SEKIMOTO M，SATO M，et al. Indispensable role for TNF-alpha and IFN-gamma at the effector phase of liver injury mediated by Th1 cells specific to hepatitis B virus surface antigen[J]. Immunology，2000，165:956-961.
[8] ISHIDA Y，KONDO T，TSUNEYAMA K，et al.The pathogenic roles of tumor necrosis factor receptor p55 in acetaminophen-induced liver injury in mice[J]. Leukoc Biol，2004，75:59-67.
[9] LOUIS H，LE MOINE O，PENY MO，et al. Production and role of interleukin-10 in concanavalin A-induced hepatitis in mice[J]. Hepatology，1997，25:1382-1389.
[10] DI MARCO R，XIANG M，ZACCONE P，et al. Concanavalin A-induced hepatitis in mice is prevented by interleukin（IL）-10 and exacerbated by endogenous IL-10 deficiency[J]. Autoimmunity，1999，31:75-83.
[11] KATO M，IKEDA N，MATSUSHITA E，et al. Involvement of IL-10，an anti-inflammatory cytokine in murine liver injury induced by concanavalin A[J]. Hepatol Res，2001，20:232-243.
[12] NAGAKI M，TANAKA M，SUGIYAMA A，et al. Interleukin-10 inhibits hepatic injury and tumor necrosis factor-and interferon-mRNA expression induced by staphylococcal enterotoxin B or lipopolysaccharide in galactosamine-sensitized mice[J]. Hepatology，1999，31:815-824.
[13] LEIFELD L，CHENG S，RAMAKERS J，et al. Imbalanced intrahepatic expression of interleukin 12，interferon gamma，and interleukin 10 in fulminant hepatitis B[J]. Hepatology，2002，36（4 Pt 1）:1001-1008.
[14] STREETZ K，LEIFELD L，GRUNDMANN D，et al. Tumor necrosis factor in the pathogenesis of human and murine fulminant hepatic failure[J]. Gastroenterology，2000，119:446-460.
[15] 中华医学会感染病学分会肝衰竭组与人工肝学组，中华医学会肝病学分会重型肝病与人工肝学组.肝衰竭诊疗指南[J]. 实用肝脏病杂志，2006，9（6）：321-324.
[16] 中华医学会传染病与寄生虫病学分会、肝病学分会.病毒性肝炎防治方案[J]. 中华传染病杂志，2001，19（1）：56-62.
[17] 纪小龙，施作霖. 诊断免疫组织化学[M].北京，军事医学科学出版社，1997:14-20.

Imbalanced intrahepatic expression of interferon gamma，tumor necrosis factor alpha，and interleukin-10 in hepatitis B virus infection patients with acute-on-chronic liver failure

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	patients with chronic hepatitis B Zhang Yingming, Shen Shuang, Tian Fei, et al.. Prediction of response to peginterferon alfa-2a by blood IFNL4 and IL-28B gene polymorphisms in [J]. Journal of Practical Hepatology, 2019, 22(6): 828-831.
[2]	Tu Jiexia, Wang An’na, Liao Ruoxi. Comparative study of interferon alpha -2b and peginterferon alpha -2a in the treatment of patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2019, 22(5): 648-651.
[3]	Zhu Yucheng, Yan Jiawei, Sun Jingkun, et al. Serum diamine oxidase level in patients with hepatitis B-induced acute-on-chronic liver failure [J]. Journal of Practical Hepatology, 2019, 22(5): 672-675.
[4]	Zhang Mei, Shi Xiuying, Li Linjuan, et al. Hepatic expression of interferon inducible protein -10 in patients with hepatitis B liver cirrhosis and hepatogenic diabetes mellitus [J]. Journal of Practical Hepatology, 2019, 22(5): 688-691.
[5]	Bai Yichun, Deng Jihong, Mei Xiaoping. Efficacy of peginterferon alfa-2b treatment and affecting response factors in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 490-493.
[6]	Wang Yuan, Dang Panyu, Wang Wei. Application of plasma exchange and continuous plasma dialysis filtration in the treatment of patients with acute-on-chronic liver failure [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 541-544.
[7]	Peng Silu, Liu Bing, Sun Hong, et al. Prognosis of patients with hepatitis B-induced acute-on-chronic liver failure [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 545-548.
[8]	Jin Jun, Song Zhenyu, Liu Jixiang. Changes of serum IL-10 and soluble intercellular adhesion molecule-1 levels in patients with hepatitis B-induced liver cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(4): 549-552.
[9]	Wang Xiaoxiao, Chen Xinyue. Therapeutic strategy for serum HBsAg clearance in suitable population of chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 309-312.
[10]	Zhong Song, Liu Yuyuan, Liu Shuren. G2D expression of peripheral blood natural killer cells in patients with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 341-344.
[11]	Wang Baodan, Li Meng, Gao Yu. Predictive factors of response to interferon-α antiviral therapy in children with chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 345-348.
[12]	Yuan Chunhui, Li Chunyu, Li Hongli. Efficacy of pegylated interferon α -2b in the treatment of patients with serum HBeAg positive chronic hepatitis B [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(3): 353-356.
[13]	Yuan Chunhui, Li Chunyu, Li Hongli, Zhao Hongna, Wen Wenhong, Meng Qingxu, Zhang Zhongxue. Impact of blood IL28B gene polymorphism on viralogic response in patients with HBeAg positive chronic hepatitis B receiving peginterferon alfa therapy [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 184-187.
[14]	Yang Zhenjie, Li Hongtao, Wang Jian, Li Xia, Chen Yuan. Efficacy of combination of pegylated interferon-α-2a and ribavirin in treatment of patients with compensated hepatitis C cirrhosis [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(2): 232-235.
[15]	Zhao Peng, Wang Lei.. Comparison of therapeutic efficacy of pegylated interferon-α in treatment of patients with different hepatitis C viral genotype infection [J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2019, 22(1): 57-60.